The Central American Gyre is a broad, weak low-pressure system that can trigger the formation of tropical storms and hurricanes during hurricane season. The National Hurricane Center is currently ...

Gyre Therapeutics' stock is volatile - I'm upholding my "Hold" rating due to uncertain long-term prospects and potential dilution from future funding needs. The company's products include Etuary, and ...

Unsurprisingly, Gyre Therapeutics, Inc.'s (NASDAQ:GYRE) stock price was strong on the back of its healthy earnings report. However, we think that shareholders may be missing some concerning details in ...

The first tropical storm of 2025 could spin up before the official start of the Atlantic hurricane season, kicking off what is predicted to be a dynamic year for hurricanes. Around the middle of May, ...

Insider trading is legal so long as the insiders report those trades to the SEC. Illegal securities trading occurs when the insider is violating a fiduciary duty or fails to report their trades.

Gyre Therapeutics, Inc. (GYRE) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of $0.05 per share. This compares to earnings of $0.02 per share a year ago.

Several systems from the hyperactive 2020 hurricane season, including many of the land-falling storms along the Gulf Coast, developed in a similar way, stemming from a breeding ground created by an ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

Disclosed in a recent SEC filing on May 15, Ye, Chief Operating Officer at Gyre Therapeutics (NASDAQ:GYRE), made a noteworthy transaction involving the exercise of company stock options. What Happened ...